IMR Press / EJGO / Volume 34 / Issue 5 / pii/1630906444995-2118329726

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Effectiveness of radiotherapy in patients with primary invasive vaginal carcinoma
Show Less
1 Gynaecologic Oncology Department, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Krakow
2 Radiation Oncology Department, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Krakow
3 Gastrointestinal and Urological Cancer Unit, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Krakow
4 Oncological Surgery Department, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Krakow
5 Diagnostic Radiology Department Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Krakow (Poland)
Eur. J. Gynaecol. Oncol. 2013, 34(5), 436–441;
Published: 10 October 2013
Abstract

Introduction: The aim of the study was to present an institutional experience in radiation therapy of primary invasive vaginal carcinoma (PIVC) patients treated in the Krakow Branch of Centre of Oncology, with special regard to treatment effectiveness and failure causes. Materials and Methods: Between February 1967 and January 2007, 162 PIVC patients were treated with radical radiotherapy in the Krakow Branch of Centre of Oncology, Maria Sklodowska-Curie Memorial Institute. Twenty-seven (16.7%) patients in Stage I0 were treated with intracavitary brachytherapy alone; for 127 (78.4%) patients in Stage I0 - IV0 intracavitary brachytherapy was combined with external radiation therapy; and eight (4.9%) patients in Stage IVA0 were given only external radiotherapy. Results: In the investigated group of 162 patients, five-year disease-free survival was observed in 46.3% of the cases. Patient age and FIGO Stage of neoplastic disease were independent prognostic factors. Five-year disease-free survival was observed in 64.9% of the patients < 60 years of age and only in 30.7% ≥ 60 years of age; and in 62.3% of PIVC patients in Stages I and II0 as compared to 19.7% of Stages III0 and IV0 cases. Among 78 patients who diedof PIVC, in 60 (76.9%) cases the cause of death was locoregional failure; in six (7.7%), locoregional failure and distant metastasis; and in 12 (15.4%), distant metastasis. Conclusions: Radiotherapy is effective treatment for PIVC patients. Age below 60 years and non-advanced neoplastic disease were independent favourable prognostic factors in the investigated group of patients. The primary cause of treatment failure was failure to achieve locoregional disease control.
Keywords
PIVC
Radiotherapy
Effectiveness
Failure
Share
Back to top